Year archive

Swedish Orphan Biovitrum — 2014 filings

All 58 regulatory filings released by Swedish Orphan Biovitrum (SOBI) in 2014, sourced directly from the official regulator.

58 Filings

2014 Period

2014 filings (58)

Filing	Released	Lang
Sobi exercises opt-in right for Elocta(TM) Regulatory Filings	2014-11-21	English
Sobi utnyttjar sin option på Elocta(TM) Regulatory Filings	2014-11-21	Swedish
Europeiska läkemedelsmyndigheten validerar ansökan om marknadsföringstillstånd för Elocta(TM) (rFVIIIFc) Regulatory Filings	2014-10-31	Swedish
Biogen Idec and Sobi announce European Medicines Agency validates Elocta(TM) (rFVIIIFc) Marketing Authorisation Application for review Regulatory Filings	2014-10-31	English
Report Publication Announcement 2014 Report Publication Announcement	2014-10-30	Swedish
Interim / Quarterly Report 2014 Interim / Quarterly Report Q3 2014	2014-10-30	English
Sobi publicerar resultaten för det tredje kvartalet 2014 Interim / Quarterly Report Q3 2014	2014-10-30	Swedish
Sobi publishes Report for the Third Quarter 2014 Interim / Quarterly Report Q3 2014	2014-10-30	English
Sobis samarbetspartner Biogen Idec ansöker om marknadsgodkännande för Elocta(TM) (rFVIIIFc) i Europa Regulatory Filings	2014-10-09	Swedish
Sobi's collaboration partner Biogen Idec files marketing authorisation application for Elocta(TM) (rFVIIIFc) in Europe Regulatory Filings	2014-10-09	English
Sobi utökar utvecklingsportfölj inom hemofili - väljer att inkludera potentiellt långverkande hemofili A-kandidat i samarbetet med Biogen Idec M&A Activity	2014-09-19	Swedish
Sobi expands Haemophilia development portfolio - elects to include potentially longer-acting Haemophilia A candidate in collaboration agreement with Biogen Idec Capital/Financing Update	2014-09-19	English
Ändring av antalet aktier och röster i Swedish Orphan Biovitrum AB (publ) Declaration of Voting Results & Voting Rights Announcements	2014-07-31	Swedish
New number of shares and votes in Swedish Orphan Biovitrum AB (publ) Declaration of Voting Results & Voting Rights Announcements	2014-07-31	English
Sobis styrelse utnyttjar återköpsbemyndigande för säkerställande av bolagets åtaganden enligt incitamentsprogram Transaction in Own Shares	2014-07-18	Swedish
Sobi's board of directors exercises authorisation for repurchase of shares for the purpose of securing the company's commitments under the incentive program Transaction in Own Shares	2014-07-18	English
Interim / Quarterly Report 2014 Interim / Quarterly Report Q2 2014	2014-07-18	Swedish
Report Publication Announcement 2014 Report Publication Announcement	2014-07-18	English
Sobi files for EU approval of Xiapex for Peyronies disease Regulatory Filings	2014-06-25	English
Sobi ansöker om EU-godkännande för Xiapex vid Peyronies sjukdom Regulatory Filings	2014-06-25	Swedish
Sobi to review preclinical data to potentially add future haemophilia A candidate to collaboration agreement with Biogen Idec M&A Activity	2014-06-16	English
Sobi granskar preklinisk data gällande en framtida läkemedelskandidat för hemofili A för att eventuellt utöka samarbetsavtalet med Biogen Idec Regulatory Filings	2014-06-16	Swedish
Amerikanska läkemedelsmyndigheten (FDA) godkänner Eloctate(TM) Regulatory Filings	2014-06-09	Swedish
The US Food and Drug Administration (FDA) approves Eloctate(TM) Regulatory Filings	2014-06-09	English
Sobi Establishes North American Office in Massachusetts Regulatory Filings	2014-06-05	English
Sobi flyttar nordamerikansk kontor till Massachusetts Regulatory Filings	2014-06-05	Swedish
Swedish Orphan Biovitrum AB (publ): Sobi appoints Kirsti Gjellan as Senior Vice President Manufacturing Operations Board/Management Information	2014-05-26	English
Swedish Orphan Biovitrum AB (publ): Sobi utser Kirsti Gjellan till Senior Vice President Manufacturing Operations Board/Management Information	2014-05-26	Swedish
Biogen Idec and Sobi to donate 1 billion international units of clotting factor to support treatment of haemophilia in developing world Earnings Release FY 2014	2014-05-12	English
Biogen Idec och Sobi donerar en miljard internationella enheter koagulationsfaktor för att stödja behandlingen av hemofili i utvecklingsländer Regulatory Filings	2014-05-12	Swedish
Swedish Orphan Biovitrum AB (publ): Annette Clancy invald i Sobis styrelse Board/Management Information	2014-05-08	Swedish
Swedish Orphan Biovitrum AB (publ): Annette Clancy joins Sobi's Board of Directors Board/Management Information	2014-05-08	English
Interim / Quarterly Report 2014 Interim / Quarterly Report Q1 2014	2014-05-08	Swedish
Interim / Quarterly Report 2014 Interim / Quarterly Report Q1 2014	2014-05-08	English
Annual Report 2013 Annual Report FY 2013	2014-04-16	Swedish
Annual Report 2013 Annual Report FY 2013	2014-04-16	English
Sobi publishes Annual Report 2013 Report Publication Announcement	2014-04-16	English
Sobis årsredovisning för 2013 publicerad Report Publication Announcement	2014-04-16	Swedish
Biogen Idec and Sobi announce positive top-line efficacy and safety results from phase-3 paediatric study of investigational therapy Eloctate(TM) (rFVIIIFc) for haemophilia A Earnings Release FY 2014	2014-04-10	English
Biogen Idec och Sobi meddelar positiva resultat gällande effekt och säkerhet från Kids A-LONG, bolagens fas-3 studie på barn av läkemedelskandidaten Eloctate(TM) (rFVIIIFc) för hemofili A Earnings Release FY 2014	2014-04-10	Swedish
Sobi becomes market authorisation holder for Xiapex in Europe Regulatory Filings	2014-04-07	English
Sobi blir innehavare av marknadsföringstillståndet för Xiapex i Europa Regulatory Filings	2014-04-07	Swedish
Notice of annual general meeting in Swedish Orphan Biovitrum AB (publ) AGM Information	2014-04-03	English
Kallelse till årsstämma i Swedish Orphan Biovitrum AB (publ) AGM Information	2014-04-03	Swedish
Sobi övertar ansvaret för Orfadin i Nordamerika och introducerar Orfadin4U(TM) M&A Activity	2014-04-01	Swedish
Sobi assumes direct responsibility for Orfadin® (nitisinone) in US and Canada and introduces Orfadin4U(TM) Regulatory Filings	2014-04-01	English
Sobi: US FDA approves Alprolix(TM) Regulatory Filings	2014-03-31	English
Sobi: Amerikanska läkemedelsmyndigheten (FDA) godkänner Alprolix(TM) Regulatory Filings	2014-03-31	Swedish
Sobi: Kiobrinas fas 3-studie nådde inte det primära effektmåttet Legal Proceedings Report	2014-03-26	Swedish
Sobi: Kiobrina pivotal phase 3 study did not meet primary endpoint Earnings Release FY 2013	2014-03-26	English
Cometriq® approved in Europe for the treatment of progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma. Regulatory Filings	2014-03-25	English
Cometriq® godkänt i Europa för behandling av progressiv, inoperabel lokalt framskriden eller metastaserande medullär sköldkörtelcancer Regulatory Filings	2014-03-25	Swedish
Kanadensiska läkemedelsmyndigheten, Health Canada, godkänner Alprolix(TM) Regulatory Filings	2014-03-21	Swedish
Health Canada approves Alprolix(TM) Regulatory Filings	2014-03-21	English
Interim / Quarterly Report 2013 Interim / Quarterly Report Q4 2013	2014-02-20	Swedish
Interim / Quarterly Report 2013 Interim / Quarterly Report Q4 2013	2014-02-20	English
Sobi publicerar sin rapport för fjärde kvartalet och bokslutskommuniké för 2013 Interim / Quarterly Report Q4 2013	2014-02-20	Swedish
Sobi publishes its Report for the Fourth Quarter and Full Year 2013 Interim / Quarterly Report Q4 2013	2014-02-20	English

Filings by year

2026 16 filings
2025 35 filings
2024 29 filings
2023 48 filings
2022 23 filings
2021 31 filings
2020 44 filings
2019 38 filings
2018 31 filings
2017 34 filings
2016 47 filings
2015 52 filings
2014 58 filings
2013 79 filings
2012 65 filings
2011 51 filings
2010 78 filings
2009 69 filings
2008 51 filings
2007 10 filings